# Protease Inhibitors and Combined Oral Contraceptive Pharmacokinetics and Pharmacodynamics

> **NCT02531321** · PHASE4 · TERMINATED · sponsor: **University of Southern California** · enrollment: 17 (actual)

## Conditions studied

- Contraception
- HIV

## Interventions

- **DRUG:** Levonorgestrel and Ethinyl Estradiol

## Key facts

- **NCT ID:** NCT02531321
- **Lead sponsor:** University of Southern California
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2015-08
- **Primary completion:** 2016-11
- **Final completion:** 2016-11-01
- **Target enrollment:** 17 (ACTUAL)
- **Why stopped:** Difficulty recruiting
- **Last updated:** 2019-05-31


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02531321

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02531321, "Protease Inhibitors and Combined Oral Contraceptive Pharmacokinetics and Pharmacodynamics". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02531321. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*